Impact of trandolapril therapy and its combination with a calcium channel blocker on plasma adiponectin levels in patients with type 2 diabetes and hypertension

Therapeutic Advances in Cardiovascular Disease

Volumn 5, Issue 4, 2011, Pages 193-197

  Rubio Guerra, Alberto F ^a   Vargas Robles, Hilda ^b   Vargas Ayala, German ^a   Rodríguez Lopez, Leticia ^a   Castro Serna, David ^a   Escalante Acosta, Bruno A ^b  

^a Mexican Group for Basic and Clinical Research Internal Medicine   (United States)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

adiponectin; fixed dose combination; hypertension; trandolapril; type 2 diabetes mellitus; verapamil

Indexed keywords

ADIPONECTIN; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADIPONECTIN; AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION; INDOLES; MALE; MIDDLE AGED; TREATMENT OUTCOME; VERAPAMIL;

EID: 79961147207     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944711415307     Document Type: Article

References (18)

1. Ahima R.S. (2008) Linking adiponectin with proteinuria. J Clin Invest 118: 1619–1622.
2. Bakris G.L. Molitch M., Hewkin A. Kipnes M. Sarafidis P. Facouhfi K. et al (2006) Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 29: 2592–2597.
3. Bakris G.L. Sowers J. (2008) on behalf of the American Society of Hypertension writing group. ASH position paper: Treatment of hypertension in patients with diabetes–an update. J Clin Hypertens 10: 707–713.
4. Dahlöf B. Sever P.S. Poulter N.R. Wedel H. Beevers D.G. Caulfield M. et al (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 366: 895–906.
5. Furuhashi M. Ura N. Higashiura K. Murakami H. Tanaka M. Moniwa N. et al (2003) Blockade of the renin–angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42: 76–81.
6. Garcia-Puig J. Ruilope L.M. Luque M. (2006) for the Avant Study Group Investigators. Glucose metabolism in patients with essential hypertension. Am J Hypertens 119: 318–326.
7. Hopkins T.A. Ouchi N. Shibata R. Walsh K. (2007) Adiponectin actions in the cardiovascular system. Cardiovasc Res 74: 1–18.
8. Kawanami D. Maemura K. Takeda N. (2004) Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells, A new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 314: 415–419.
9. Nomura S. Inami N. Kimura Y. Omoto S. Shouzu A. Nishikawa M. et al (2007) Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens 21: 38–44.
10. Opie L.H. Schall R. (2004) Old antihypertensives and new diabetes. J Hypertens 22: 1453–1458.
11. Patel J.V. Lim H.S. Hughes E.A. Lip G.Y. (2007) Adiponectin and hypertension: a putative link between adipocyte function and atherosclerotic risk? J Hum Hypertens 21: 1–4.
12. Pepine C.J. Handberg E.M. Cooper-De Hoff R.M. (2003) for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease (INVEST): a randomised controlled trial. JAMA 290: 2805–2816.
13. Rothenbacher D. Brenner H. März W. Koening W. (2005) Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 26: 1640–1646.
14. Rubio-Guerra A.F. Castro-Serna D. Elizalde-Barrera C.I. Ramos-Brizuela L.M. (2009) Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors. Integrated Blood Pressure Control 2: 55–62.
15. Rubio-Guerra A.F. Vargas-Robles H. Maceda-Serrano A. Vargas-Ayala G. Rodriguez-Lopez L. Escalante-Acosta B.A. (2010) Correlation between the levels of circulating adhesion molecules and atherosclerosis in hypertensive type-2 diabetic patients. Clin Exp Hypertens 32: 308–310.
16. Rubio-Guerra A.F. Vargas-Robles H. Vargas-Ayala G. Rodríguez-Lopez L. Escalante-Acosta B.A. (2008) The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes. Clin Exp Hypertens 30: 682–688.
17. Taylor E.N. Hu F.B. Curham G.C. (2006) Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 29: 1065–1070.
18. Wang Z.V. Scherer P.E. (2008) Adiponectin, cardiovascular function and hypertension. Hypertension 51: 8–14.